Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer
暂无分享,去创建一个
Pierre Drion | Guy Jerusalem | Andrei Turtoi | P. Delvenne | A. Blomme | B. Costanza | V. Castronovo | A. Turtoi | P. Maris | G. Jerusalem | A. Bellahcène | Philippe Delvenne | Pamela Maris | Arnaud Blomme | Ana Perez Palacios | Brunella Costanza | Akeila Bellahcène | Elettra Bianchi | Stephanie Gofflot | Giovanna Elvi Trombino | Emmanuel Di Valentin | Pino G. Cusumano | Sylvie Maweja | Eric Lifrange | Vincent Castronovo | P. Cusumano | E. Di Valentin | P. Drion | E. Lifrange | G. Trombino | S. Maweja | E. Bianchi | S. Gofflot | A. Palacios
[1] K. Schwertfeger,et al. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis , 2009, Breast Cancer Research.
[2] V. Castronovo,et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. , 1998, Journal of the National Cancer Institute.
[3] D. Heinegård,et al. Identification and Characterization of Asporin , 2001, The Journal of Biological Chemistry.
[4] Gregory J Tsongalis,et al. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. , 2013, The American journal of pathology.
[5] J. Massagué,et al. The logic of TGFβ signaling , 2006 .
[6] M. Nakajima,et al. Binding characteristics of the osteoarthritis-associated protein asporin , 2010, Journal of Bone and Mineral Metabolism.
[7] R. Iozzo,et al. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine‐rich tandem motifs , 2008, International journal of cancer.
[8] L. Schaefer,et al. The matricellular functions of small leucine-rich proteoglycans (SLRPs) , 2009, Journal of Cell Communication and Signaling.
[9] N. Ambartsumian,et al. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts , 2010, BMC Cancer.
[10] E. Giannoni,et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. , 2012, Cancer research.
[11] E. Bruera,et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. , 2014, The Lancet. Oncology.
[12] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[13] J. Massagué,et al. TGFβ in Cancer , 2008, Cell.
[14] D. Moher,et al. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.
[15] W. Gerald,et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.
[16] P. Sime,et al. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[17] P. Kischel,et al. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis , 2008, International journal of cancer.
[18] H. Alexander,et al. Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .
[19] Johan Staaf,et al. GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.
[20] Carlos L. Arteaga,et al. Targeting the TGFβ signaling network in human neoplasia , 2003 .
[21] Roger R. Gomis,et al. TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.
[22] H. Shah,et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. , 2014, Neoplasia.
[23] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[24] P. Clézardin,et al. Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA1) Activation in Human Breast and Prostate Cancers , 2014, PloS one.
[25] P. Leder,et al. MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. , 2002, Cancer research.
[26] Yusuke Nakamura,et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis , 2005, Nature Genetics.
[27] WM Kast,et al. Effects of TGF-β on the immune system: implications for cancer immunotherapy , 1999, Leukemia.
[28] C. Hill,et al. Smad3 Protein Levels Are Modulated by Ras Activity and during the Cell Cycle to Dictate Transforming Growth Factor-β Responses* , 2009, Journal of Biological Chemistry.
[29] P. Delvenne,et al. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. , 2011, Journal of proteome research.
[30] M. Young,et al. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[31] King-Jen Chang,et al. Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis , 2011, PloS one.
[32] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[33] B. Orr,et al. Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate , 2011, Oncogene.
[34] H. Moses,et al. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk , 2012, Breast Cancer Research.
[35] J. Massagué,et al. The logic of TGFbeta signaling. , 2006, FEBS letters.
[36] R. Iozzo,et al. Decorin: a guardian from the matrix. , 2012, The American journal of pathology.
[37] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[38] A. Greenberg,et al. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. , 1993, The American journal of pathology.
[39] Sebastian Schneckener,et al. Prediction Errors in Learning Drug Response from Gene Expression Data – Influence of Labeling, Sample Size, and Machine Learning Algorithm , 2013, PloS one.
[40] P. Kischel,et al. A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer*S , 2006, Molecular & Cellular Proteomics.
[41] W. Coleman,et al. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. , 2013, The American journal of pathology.
[42] P. Delafontaine,et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.
[43] C. Dinarello. Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.
[44] A. Børresen-Dale,et al. Triple-negative breast cancer and the need for new therapeutic targets. , 2013, The American journal of pathology.
[45] Aleksandra M. Michalowska,et al. Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model , 2007 .
[46] A. Mantovani,et al. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. , 1990, Cancer research.
[47] P. Fritz,et al. Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients , 2004, Clinical Cancer Research.
[48] D. Proia,et al. Stroma: Tumor Agonist or Antagonist , 2005, Cell cycle.
[49] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[50] Aleksandra M. Michalowska,et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. , 2007, Cancer research.
[51] C. Corless,et al. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. , 2005, The Journal of clinical investigation.
[52] Brian Bierie,et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.
[53] R. Weinberg,et al. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Delvenne,et al. Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. , 2012, Journal of proteome research.
[55] M. Mareel,et al. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. , 2014, Seminars in cancer biology.
[56] N. Fusenig,et al. Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.
[57] I. Cuthill,et al. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research † , 2012, Osteoarthritis and cartilage.
[58] Camille Stephan-Otto Attolini,et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.
[59] E. Gelmann,et al. Differentiation state and invasiveness of human breast cancer cell lines , 2004, Breast Cancer Research and Treatment.
[60] P. ten Dijke,et al. TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis , 2011, Journal of Mammary Gland Biology and Neoplasia.
[61] Brian Bierie,et al. TGF- and cancer , 2006 .
[62] Brian Bierie,et al. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.
[63] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] M. Shekhar,et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.
[65] Brian Bierie,et al. TGF-beta and cancer. , 2006, Cytokine & growth factor reviews.
[66] G. Bhagat,et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. , 2008, Cancer cell.
[67] R. Matoba,et al. Expression profile of active genes in human periodontal ligament and isolation of PLAP-1, a novel SLRP family gene. , 2001, Gene.
[68] C. Arteaga,et al. Targeting the TGF beta signaling network in human neoplasia. , 2003, Cancer cell.
[69] J. Massagué,et al. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.
[70] M. Young,et al. Regulation, regulatory activities, and function of biglycan. , 2004, Critical reviews in eukaryotic gene expression.